Glucose Test Strip
Thank you for visiting Glucoseteststrip.net.
We cannot overstress the importance of ensuring you have proper diagnosis and medical clearance before using any glucose test device as part of a treatment programme. The information presented here is for educational and information use and should not substitute for professional medical advice.
If using test strips and meters it is critical that you are aware of the differences and risks associated with various meters. The information from the FDA reprinted below should be read carefully.
The Food and Drug Administration (FDA) warned health care providers and patients about a serious issue with certain test strips and meters used to monitor blood glucose levels. In a public health notification issued on August 14, 2009, the FDA explained that there is a problem with tests that use a chemical called glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) to measure levels of glucose in the blood.
Not all glucose meters and test strips use the GDH-PQQ method and only those that do are included in the FDA notification. (Other methods include glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD), and hexokinase.) For a list of glucose meters and test strips that use GDH-PQQ methodology, click here.
Test strips and testing meters that use the GDH-PQQ method erroneously measure other types of sugars such as maltose, xylose, and galactose in addition to glucose. These non-glucose sugars are found in certain drugs and other preparations given to some patients as treatment. Since GDH-PQQ test strips measure other sugars in addition to glucose, they can give falsely elevated results. If action is taken in response to the results, such as administering more insulin, then hypoglycemia and, rarely, coma and death may result. The FDA has received reports of 13 deaths in the years 1997-2009 where it was documented that interference from other sugars resulted in falsely elevated results from tests using GDH-PQQ methodology.
Glucose meters and test strips are often used to measure glucose levels at patients’ bedsides — referred to as “point of care testing” (POCT)— and for self-monitoring by diabetics. Tests for glucose that are performed in clinical laboratories do not use the GDH-PQQ method and are not affected by sugars other than glucose.
In the notification, the FDA cautions health care practitioners that GDH-PQQ test strips not be used to monitor the glucose levels of patients receiving drugs and other therapies containing non-glucose sugars. These patients should be monitored with tests performed in clinical laboratories or with other meters that do not use GDH-PQQ methodology. Some of the therapies in this category include icodextrin, a sugar used in some peritoneal dialysis solutions, and maltose, used in some immunoglobulin preparations. Because these medications are administered through a vein (intravenously) or are part of a same-day medical procedure, they typically are given in an inpatient or clinic setting. For a more complete list of these therapies and for additional details about the issue see: FDA Public Health Notification: Potentially Fatal Errors with GDH-PQQ Glucose Monitoring Technology.
The FDA urges diabetic patients and their caregivers to talk to their health care providers about drug therapies they are receiving and to know what type of test strips or meter they use. This may be done by checking the instructions that accompany the test strips or the glucose meter’s packaging. Read more about the recommendations at: FDA Advice for Patients: Serious Errors with Certain Blood Glucose Meters and Strips.
The US Food and Drug Administration (FDA) has approved blood glucose test strips (FreeStyle Lite; Abbott Diabetes Care) to help patients better manage their diabetes by minimizing the potential for interference by other sugars.
The glucose-specific test strips use the glucose dehydrogenase with flavin-adenine dinucleotide (GDH-FAD) enzyme, thereby avoiding falsely elevated readings that can result from glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ)–based methods that can be affected by common nonglucose sugars, such as maltose or galactose.
Compatible with all FreeStyle Lite monitoring systems, the new test strips also feature a proprietary tapered design (ZipWik) intended to ensure quicker blood application and decrease error messages and wastage.
FREE STYLE LITE 50 NFRS
- Factory-sealed, brand new
MANUFACTURER: ABBOTT DIABETES CARE. INDICATIONS: Freestyle Lite Blood Glucose Test Strips Medicare/Medicaid Test Strips, Model: 70819 * Freestyle Lite Blood Glucose Monitoring System * No Coding Required. * For in vitro diagnostic use only. * Virtually Pain-Free Testing. * 50 Test Strips – Use only with the FreeStyle Lite System. * For self testing. * Do not use if expiration date has passed. * Do not refrigerate or freeze. * Store at room temperature below 86 Degrees F (30 Degrees C). * Do not use if box seal is broken or missing. * Chemical Composition – PQQ Glucose Dehydrogenase Less than 1.0 Unit. Other ingredients (buffer, mediator, etc.) Less than 0.01mg. DIRECTIONS: Please read the packaging insert before using this product. Do not refrigerate or freeze. Please read the package insert before using this product. WARNINGS: Do not use if box seal is broken or missing.
Price: $ 55.99
“By minimizing interference and providing a better testing experience, Abbott is delivering on what patients and health care professionals demand in diabetes care, especially for people who use insulin to manage their diabetes,” stated Abbott Diabetes Care, in a company news release.
We recommend American Diabetes Association as a good source of general diabetes and diabetic diet information
